Abstract
Widespread high-throughput testing for identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RT-PCR has been a foundation in the response to the coronavirus disease 2019 (COVID-19) pandemic. Quality assurance metrics for these RT-PCR tests are still evolving as testing is widely implemented. As testing increases, it is important to understand performance characteristics and the errors associated with these tests. Herein, we investigate a high-throughput, laboratory-developed SARS-CoV-2 RT-PCR assay to determine whether modeling can generate quality control metrics that identify false-positive (FP) results due to contamination. This study reviewed repeated clinical samples focusing on positive samples that test negative on re-extraction and PCR, likely representing false positives. To identify and predict false-positive samples, we constructed machine learning–derived models based on the extraction method used. These models identified variables associated with false-positive results across all methods, with sensitivities for predicting FP results ranging between 67% and 100%. Application of the models to all results predicted a total FP rate of 0.08% across all samples, or 2.3% of positive results, similar to reports for other RT-PCR tests for RNA viruses. These models can predict quality control parameters, enabling laboratories to generate decision trees that reduce interpretation errors, allow for automated reflex testing of samples with a high FP probability, improve workflow efficiency, and increase diagnostic accuracy for patient care.
Original language | English (US) |
---|---|
Pages (from-to) | 1085-1096 |
Number of pages | 12 |
Journal | Journal of Molecular Diagnostics |
Volume | 23 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2021 |
Bibliographical note
Funding Information:We thank Robyn Kincaid and Drs. Sophie Arbefeville, Aaron Barnes, and Ryan Langlois for helpful discussion in the preparation of this article; the University of Minnesota Genomics Center (including Benjamin Auch, Ray Watson, Lindsey Gengelbach, Darrell Johnson, Dr. Patrick Grady, Dr. Daryl Gohl, and Shea Anderson) and the M Health Molecular Diagnostic Laboratory and Infectious Disease Diagnostic Laboratory (including Kylene Karnuth, Michaela Leary, Shannon Gascoigne, and Jessica Gunderson) for staffing, support, and testing performance of the SARS-CoV-2 testing.
Publisher Copyright:
© 2021 Association for Molecular Pathology and American Society for Investigative Pathology
PubMed: MeSH publication types
- Journal Article